期刊
CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY
卷 -, 期 -, 页码 -出版社
HUMANA PRESS INC
DOI: 10.1007/s12016-023-08968-y
关键词
Anaphylaxis; Desensitization; Hypersensitivity reactions; Taxanes
Taxanes in cancer treatment often cause hypersensitivity reactions, limiting their use. Drug desensitization has allowed the reintroduction of taxanes in highly allergic patients. A systematic review was conducted to assess the safety and efficacy of rapid drug desensitization (RDD) for taxanes hypersensitivity reactions (HSR). The study identified 25 studies involving 976 patients with initial HSR to paclitaxel and docetaxel, and found that RDD was a safe and effective procedure with high success rates. Standardized protocols should be implemented for widespread use.
Taxanes in the treatment of cancer are associated with a significant incidence of hypersensitivity reactions, which may preclude their use in patients in need of first line therapy. Drug desensitization induces transient immunological tolerance and has allowed the reintroduction of taxanes in highly allergic patients. Increase the knowledge of hypersensitivity reactions (HSR) during the administration of taxanes. A systematic review regarding the safety and efficacy of rapid drug desensitization (RDD) for taxanes HSR. The study followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, was registered in PROSPERO(CRD42021242324) and a comprehensive search was conducted in Medline, Embase, Web of Science and Scopus databases. 25 studies encompassing 10 countries were identified and 976 patients with initial HSR to paclitaxel (n = 707) and docetaxel (n = 284), that underwent a total of 2,396 desensitizations. The most common symptoms were cutaneous (74.6%) with paclitaxel and respiratory (72.6%) with docetaxel. Severe initial hypersensitivity reactions including anaphylaxis occurred in 39.6% and 13% of paclitaxel and docetaxel cases respectively and during the first (87.4%) or second exposure (81.5%). Patients tolerated well RDD and breakthrough reactions (BTR) occurred in 32.2% of paclitaxel-treated patients and in 20.6% of docetaxel treated patients. Premedications included corticosteroids, antihistamines and leukotriene receptor antagonists. The most commonly used protocol was the BWH 3 bags 12 steps, all protocols showed a success rate between 95-100%, with no reported deaths. RDD is a safe and effective procedure in patients with HSR to taxanes and protocols should be standardized for wide range implementation.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据